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Summary
Advancing age is associated with a progressive loss of skeletal
muscle (SkM) mass and function. Given the worldwide aging
demographics, this is a major contributor to morbidity, escalating
socio-economic costs and ultimately mortality. Previously, it has
been established that a decrease in regenerative capacity in
addition to SkM loss with age coincides with suppression of
insulin/insulin-like growth factor signalling pathways. However,
genetic or pharmacologicalmodulations of these highly conserved
pathways have been observed to significantly enhance life and
healthspan in various species, including mammals. This therefore
provides a controversial paradigm in which reduced regenerative
capacity of skeletal muscle tissue with age potentially promotes
longevity of the organism. This paradox will be assessed and
considered in the light of the following: (i) the genetic knockout,
overexpression and pharmacological models that induce lifespan
extension (e.g. IRS-1/s6K KO, mTOR inhibition) versus the impor-
tant role of these signalling pathways in SkM growth and
adaptation; (ii) the role of the sirtuins (SIRTs) in longevity versus
their emerging role in SkM regeneration and survival under
catabolic stress; (iii) the role of dietary restriction and its impact
on longevity versus skeletal muscle mass regulation; (iv) the
crosstalk between cellular energymetabolism (AMPK/TSC2/SIRT1)
and survival (FOXO) versus growth and repair of SkM (e.g. AMPK
vs. mTOR); and (v) the impact of protein feeding in combination
withdietary restrictionwill bediscussedasapotential intervention
to maintain SkM mass while increasing longevity and enabling
healthy aging.
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Sarcopenia: demographics and impact on quality of
life in humans
Life expectancy is increasing rapidly in many countries. As a conse-
quence, there are a greater proportion of older people making up our
global population. In the UK, 10 million people are currently over
65 years of age, with the latest projections suggesting that this will
increase to 19 million people by 2050 (Cracknell, 2013). Age is the
primary risk factor for a multitude of pathological conditions, including
Alzheimer’s disease, cardiovascular disease, type II diabetes and sarco-
penia. Sarcopenia is the age-related loss of Skeletal Muscle (SkM) mass
and function (Rosenberg, 1997). Muscle loss is evident in sedentary
humans at 25 years of age, with a 10% loss in peak lean SkM mass at
40 years of age, which increases to 40% at 70 years of age (Porter
et al., 1995). Indeed, from age 50, muscle mass is lost at a rate of 1–2%
per year (Hughes et al., 2001). This loss impacts negatively on functional
and metabolic performance, maximal strength and muscle quality
(Renault et al., 2002; Morse et al., 2005a,b; Rossi et al., 2008).
Importantly, loss of functional capacity in skeletal muscle with age is
strongly correlated with decreased quality of life and increased frailty,
morbidity and early mortality (Rantanen et al., 2003). Given that
approximately 40–50% of the population over 80 years of age suffers
from sarcopenia, this condition has been recognized as a major geriatric
clinical disorder (Cruz-Jentoft et al., 2010). Thus, ameliorating age-
related SkM wasting is of high clinical importance if we are to improve
quality of life and ultimately reduce the socio-economic impact of
sarcopenia.
Overview and Rationale
This review will focus on the cellular and molecular mechanisms that
underpin age-related muscle loss and will debate the trade-off that may
occur between skeletal muscle maintenance and survival into old age
versus whole organism life/healthspan. This concept emerges from the
body of research investigating the molecular modulators of aging. It
focuses on genetic knockout (KO) of IRS-1 and p70S6K1 as well as
transgenic models such as FOXO, SIRT1 and finally pharmacological
modulation including mTOR inhibition and sirtuin activation. All of these
models have been shown to extend both lifespan and healthspan.
Importantly however, all of these pathways are also inextricably shared
with those that modulate skeletal muscle mass maintenance. Therefore,
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this review will seek to discuss the hypertrophic, degradative and sirtuin
pathways in relation to their modulatory regulation of lifespan,
healthspan and muscle cell survival particularly in inflamed aged
environments. Finally, the potential importance of optimizing dietary
restriction and amino acid uptake to ameliorate the reduction in SkM
mass while promoting healthy aging will be discussed.
Insulin-like growth factors (IGFs) and skeletal
muscle
Overview of IGF’s and their role in skeletal muscle mass
regulation
The insulin-like growth factor (IGF) family consists of the ligands, IGF-I
and IGF-II, the type I and type II IGF cell surface receptors, six specific
high-affinity binding proteins (IGFBP-1 to IGFBP-6), IGFBP proteases and
other IGFBP-interacting molecules (Holly et al., 2000). They have a wide
range of biological functions including embryonic, foetal and adult SkM
development (reviewed in Stewart & Rotwein, 1996a). In vivo rodent
studies have shown that KO of IGF-I, IGF-II or the IGF-I receptor (IGF-IR)
results in animals that are phenotypically small for their gestational age
with significant decreases in SkMmass and neonatal lethality (Nabeshima
et al., 1993; Lau et al., 1994; Stewart & Rotwein, 1996a,b). Alterna-
tively, increasing circulating IGF-I expression in transgenic mice results in
SkM hypertrophy (Matthews et al., 1988). Furthermore, KO of IGF-IIR
also results in SkM overgrowth; as IIR acts as a clearance receptor for IGF-
II, thus its removal leads to an increase in circulating IGF-II and
subsequent hypertrophy (Lau et al., 1994). Our group has extensively
characterized the multifaceted roles of the IGF system where they are
fundamental in the proliferation, survival, differentiation and hypertrophy
of primary human and mouse SkM cells (Stewart et al., 1993; James
et al., 1996; Stewart et al., 1996; Stewart & Rotwein, 1996b; Stewart
et al., 1999a,b; Foulstone et al., 2001, 2003a,b, 2004; Grohmann et al.,
2005; Saini et al., 2008; Stewart & Pell, 2010; Al-Shanti & Stewart, 2011;
Saini et al., 2012; Sharples et al., 2013; Player et al., 2014) (Reviewed in
Scime & Rudnicki, 2006). Skeletal muscle-derived IGF-I is also important
in adult muscle hypertrophy, as demonstrated using liver IGF-I-deficient
(LID) mice (Matheny et al., 2009). In this study, despite an 80% reduction
in total circulating levels of IGF-I in LID versus control (L/L) mice, following
16 weeks of hypertrophy inducing resistance exercise there was no
difference in locally produced IGF-I mRNA or IGF-IR activation between
groups (Matheny et al., 2009). Despite these compelling data, the
importance of IGF-I in mechanical load-induced hypertrophy following
resistance exercise and the development of animal models of nonphys-
iological hypertrophy have been recently debated. This controversy is
reviewed by our group elsewhere, and it not the focus of this current
review (Stewart & Pell, 2010; Sharples & Stewart, 2011).
Reductions in IGF-I and associated signalling in aging skeletal
muscle
With sarcopenia, a 33% reduction in circulating IGF-I (Benbassat et al.,
1997) and a 45% decline in SkM-derived IGF-I mRNA are observed in
older (70  0.3 years) vs. younger (20  0.3 years) human males (Leger
et al., 2008). A corresponding attenuation in downstream intracellular
signalling targets involved in protein synthesis with age has also been
described. These include reductions in the activity of PI3K, Akt, mTOR,
p70S6K1, 4E-BP1 and EIF2B in older vs. younger counterparts (Terada
et al., 1994; Welsh et al., 1997; Pallafacchina et al., 2002; Cuthbertson
et al., 2005; Leger et al., 2008). With impairments of these signalling
pathways also observed with age following muscle contraction (Fry
et al., 2011), a recent study using mouse models attempted to
recapitulate declining human serum IGF-I concentrations with age. It
should be noted that in rodents, serum IGF-I levels are consistently high
and do not decrease until very old age when sarcopenia is observed,
whereas in humans, serum IGF-I is highest during adolescence and
declines earlier in the life course, starting in middle age and paralleling
the onset of sarcopenia. This study suggested that mice with reduced
serum IGF-I at 1 year of age had significantly deteriorated healthspans.
They exhibited increased liver weight and inflammation and increased
incidence of hepatic tumours. Importantly, in SkM tissue, increased
oxidation of proteins was observed, indicative of increased oxidative
stress (Gong et al., 2014), overall suggesting an important role for IGF-I
in reducing some, but not all (see below), age-associated pathologies.
We have recently developed and begun to characterize the roles of the
IGFs, their receptors and modulatory binding proteins in an in vitromurine
cell model of SkM aging via the following: (i) comparisons of parental
(older) vs. daughter (younger) cell populations and (ii) multiple population
doublings as a way of artificially aging cells (Sharples et al., 2010, 2011,
2012, 2013). These studies demonstrated that IGF binding protein levels
are increased in cells that display aging phenotypes via mechanisms that
ultimately reduce the activity of Akt (Sharples et al., 2011, 2013). These
observations correspond with impaired differentiation and hypertrophy of
myotubes (Sharples et al., 2010, 2011, 2012; Deane et al., 2013). These
phenotypes are also observed in primary human SkM cells isolated from
aged vs. young donors (Collins et al., 2007; Bigot et al., 2008; Pietran-
gelo et al., 2009; Beccafico et al., 2010). These effects correspond with a
loss of myogenicity (Hidestrand et al., 2008) in the face of unchanged
telomere length and telomerase activity (O’Connor et al., 2009).
Together, the majority of evidence (both in vitro and in vivo) therefore
points towards the need for IGF-I and activation of its downstream
signalling pathways to maintain skeletal muscle mass across the lifespan.
Reduced Insulin/Insulin-like-Growth Factor
Signalling (IIS): enhanced longevity vs. reduced
muscle mass in aging skeletal muscle
IGF and Insulin Receptor Substrate (IRS-1)
Reductions in IGF-I activity with age are associated with reductions in SkM
size and function. However, reduced signalling through the IIS pathway is
also associatedwith increased lifespan and healthspan inmodel organisms
(Clancy et al., 2001; Holzenberger et al., 2002; Barbieri et al., 2003; Tatar
et al., 2003; Giannakou & Partridge, 2007; Piper et al., 2008; Selman
et al., 2008; Vallejo et al., 2009; Kenyon, 2011; Selman et al., 2011). For
example, both female and male mice globally lacking insulin receptor
substrate 1 (Irs1/) are long lived (Selman et al., 2008, 2011). Female
mice lived 32% longer compared to wild-type controls, equating to a
mean lifespan of 971 days in the Irs1/mice compared with 738 days in
wild-type control animals. Interestingly, Irs1/mice showed resistance to
several parameters associatedwith aging, including bone, skin,metabolic,
immune and motor dysfunction (Selman et al., 2008). Thus, Irs1/mice,
in commonwith several other long-livedmodels, enjoy a greater period of
their life free from various age-associated pathologies (Selman and
Withers 2011). Importantly, Irs-1/ mice display reduced growth
compared to wild-type animals perhaps due to the important role for
IRS-1 in embryonic and postnatal growth (Withers et al., 1998, 1999).
Furthermore, mice with growth hormone (GH)/IGF-I defects, while
phenotypically growth retarded compared with wild-type littermates,
also exhibit enhanced longevity, lower DNA mutation frequencies, higher
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DNA excision repair and secondary attenuation of IIS (Bates & Holder,
1988; Pell & Bates, 1992; Bartke & Brown-Borg, 2004; Bartke, 2005;
Garcia et al., 2008; Garinis et al., 2009; Masternak et al., 2009; Page
et al., 2009).
While there are clear benefits of reduced IIS signalling for lifespan and
aspects of healthspan, as eluded to above, reductions in SkM mass
correspond with decreases in IGF-I with age. Indeed, some studies
suggest that bone, cardiac muscle and other tissues display aged
characteristics when IGF-I is impaired (Adamo and Farrar, 2006; Anversa,
2005; Ceda et al., 2005; Geusens and Boonen, 2002). Indeed, Irs1/
mice have reduced body weight and fat mass compared to age-matched
controls (Pete et al., 1999; Selman et al., 2008) with reduced gastroc-
nemius SkM weight that is proportionately greater than the decrease
seen in total body weight (Pete et al., 1999). Irs1/ mice are, however,
more resilient to age-associated osteoporosis compared to controls,
which may account somewhat for this discrepancy. A recent study using
an inducible liver-derived IGF KO mouse, allowing temporal reductions
of IGF of 70% in the serum, showed that lower IGF from the age of
1 year resulted in greater oxidative stress in SkM, accelerated bone loss
and reduced lifespan (Gong et al., 2014). Indeed, across 31 genetically
diverse inbred mouse strains, lower serum IGF-I was associated with
enhanced longevity (Yuan et al., 2009). Furthermore, human population
studies suggest that reductions in IGF-I at young age but elevations at
old age might maximize healthy lifespan, reviewed in Yang et al. (2005).
To the authors’ knowledge, the only study to investigate potential
mechanisms of SkM adaptation with IRS-1 loss suggested that it did not
affect glucose uptake or GLUT1/4 function in electrically stimulated
mouse muscle (Dumke et al., 2001). Skeletal muscle mass or synthetic/
degradative signalling was, however, not investigated in this study.
Overall, it is clear that reductions in IIS enhance lifespan and delay some
aging-associated parameters yet perhaps results in small body size that is
characterized by both reduced fat mass and potentially, proportionally
smaller SkM mass. However, more investigation into SkM mass and the
corresponding cellular signalling in Irs1/ mice into old age is required
in the near future to understand the potential crosstalk between the
mechanisms that control increased lifespan and healthspan while
contributing to reductions in SkM mass with age.
Mammalian target of Rapamycin (mTOR)
In addition to reduced IIS, reduced signalling through the target of
rapamycin (TOR) signalling pathway has also been shown to modulate
lifespan and increase healthspan in model organisms (Kapahi et al., 2004;
Kaeberlein et al., 2005; Powers et al., 2006; Hansen et al., 2007; Harrison
et al., 2009; Anisimov et al., 2010; Bjedov et al., 2010;Miller et al., 2011;
Robida-Stubbs et al., 2012; Zhang et al., 2014). Longevity in humans is
also associated with reduced mTOR signalling (Slagboom et al., 2011;
Passtoors et al., 2013). The TOR or mTOR (mammalian target of
rapamycin) is, however, a key regulator of SkM growth where it also
plays a central role in the crosstalk between growth and metabolism in a
wide variety of cell types (Inoki et al., 2003) and SKM (most recently see
Hamilton et al., 2014). Mammalian target of rapamycin regulates its
hypertrophic effects in SkM through the phosphorylation of downstream
effectors such as P70S6 kinase 1 (S6K1) and eIF4E-binding protein1
(4E-BP1) (reviewed in Schiaffino et al., 2013). Their roles in SkM growth
following contraction and mechanical load-induced hypertrophy, syner-
gistic ablation, myotube hypertrophy and amino acid sensing are also well
defined (Fujita et al., 2007; Drummond et al., 2009; Willett et al., 2009;
Goodman et al., 2011; Miyazaki et al., 2011; Philp et al., 2011; Jacobs
et al., 2013; Hamilton et al., 2014). In older people, mTOR becomes less
responsive to contraction-induced activation (via resistance exercise),
compared with young adults (Fry et al., 2011). The activity of mTOR in
response to amino acid feeding is also impaired in older individuals, a
phenomenon known as ‘anabolic’ resistance (Cuthbertson et al., 2005).
Rapamycin-induced inhibition of mTOR has, however, been shown to
increase lifespan in yeast, drosophila and mice (Powers et al., 2006;
Harrison et al., 2009; Anisimov et al., 2010; Bjedov et al., 2010; Miller
et al., 2011; Robida-Stubbs et al., 2012; Wilkinson et al., 2012).
Further, rapamycin diminishes a range of aged-related pathologies
(reviewed by Johnson et al., 2013b), and despite a contentious study
claiming that it does not (Neff et al., 2013), the wide consensus is that
appropriate modulation of mTOR signalling could be an important route
of intervention to slow aging and increase healthspan (reviewed by
Johnson et al., 2013a). However, in skeletal muscle rapamycin-induced
inhibition of mTOR has been shown to impair myogenic differentiation
(Willett et al., 2009), blunt the anabolic response to overload and
nutrients (Goodman et al., 2011), with muscle-specific inactivation of
mTOR leading to myopathy (Risson et al., 2009). These data therefore
suggest, perhaps paradoxically, that despite inhibition of mTOR increas-
ing lifespan and improving many age-related pathologies, mTOR
signalling plays a critical role in maintaining SkM mass and anabolism.
Despite this, the only study that has so far investigated muscle size and
function in mice with advancing age, suggests that muscle cross-
sectional area and grip/paw strength were unaffected by a 16-month
treatment of rapamycin vs. aged-matched controls (Neff et al., 2013).
Similar to rapamycin-induced mTOR inhibition, global deletion of the
ribosomal protein S6K1 in mice, a downstream effector of mTOR, also
increases lifespan and improves healthspan in mice (Selman et al., 2009).
In contrast to rapamycin treatment having no impact on muscle size
(Neff et al., 2013), S6K1(/) myotubes are smaller, despite having a
normal number of nuclei, and their response to a hypertrophic stimuli of
IGF-I or nutrients is blunted (Ohanna et al., 2005). Further, deletion of
S6K1 in mice induces SkM atrophy even in the presence of high nutrient
availability via AMPK activation, where AMPK inhibition in S6K1-
deficient myotubes restores SkM growth via increases in myotube
diameter and sensitivity to nutrient signals (Aguilar et al., 2007). In aged
human SkM, S6K1 is downregulated in response to amino acid feeding
(Cuthbertson et al., 2005) and attenuated in old vs. young rodents
during recovery from immobilization-induced atrophy (Morris et al.,
2004). S6K1 is also reduced in contracting aged SkM in comparison with
young muscle, suggesting it plays an important role in SkM protein
synthesis, which is hampered with age (Parkington et al., 2004; Kumar
et al., 2009). However, surprisingly little is currently known about
whether basal muscle maintenance and function is altered in the context
of aging in long-lived mTOR mutant or, as discussed, rapamycin-treated
mice. Studies examining protein synthesis, protein degradation and SkM
function in long-lived mouse models are urgently required if we are to
increase our understanding of the potential trade-off between longevity
and muscle function. Depicted in Figure 1 (Fig. 1).
Sirtuins: divergent roles in the modulation of
lifespan vs. skeletal muscle mass
Sirtuins and their roles in aging and longevity
Significant recent research effort has focused on elucidating the various
roles of sirtuins (silent information regulator 1–7; Sir1-7) in aging.
Sirtuins are a group of seven highly conserved protein deacetylases
involved in the process of chromatin remodelling and gene regulation
(see Morris, 2013). They have also been shown to have pathophysiological
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relevance in cancer, obesity, SkM, inflammation and neurodegeneration
(Rodriguez & Fraga, 2010; Schug & Li, 2011; Park et al., 2012; Donmez
& Outeiro, 2013). There is emerging evidence that these proteins may
regulate SkM mass, potentially through alterations in IGF-I and associ-
ated signalling (discussed below). The metazoan Sir2 proteins are
recognized, somewhat controversially, for their role in regulating lifespan
in yeast, worms and fruit flies (Kaeberlein et al., 1999; Burnett et al.,
2011; Viswanathan & Guarente, 2011). The rodent homologue of Sir2,
SIRT1, does not increase lifespan in mice, although overexpression does
improve healthspan (Herranz et al., 2010). More specifically, neural-
specific SIRT1 overexpression has been shown to increase lifespan and
delay aspects of aging relative to wild-type littermates (Satoh et al.,
2013). Downregulation of SIRT1 also induces an aging phenotype
(Sommer et al., 2006). Activation, rather than overexpression of SIRT1
using a small molecular activator (resveratrol), reportedly reduces age-
related ill health in ad libitum fed old mice, if administered from the
middle age, it is, however, without impact on lifespan (Pearson et al.,
2008; Miller et al., 2011). Under more pathological conditions, resve-
ratrol administration does extend lifespan, specifically in mice placed on
high fat diets (Baur et al., 2006). It is worth stating here that resveratrol
has pleiotropic cellular targets and therefore, effects cannot always be
directly linked to SIRT activation per se and results should be interpreted
with this caveat in mind. Interestingly however, SIRT6, when overex-
pressed in male mice, has also been attributed to increased lifespan
(Kanfi et al., 2012b) and short-lived phentoypes are evident in SIRT6 KO
animals (Mostoslavsky et al., 2006).
Sirtuins and their impact on IGF signalling and skeletal muscle
In terms of SkM growth and protein synthesis, evidence exists,
implicating SIRT1 and SIRT6 as negative regulators of IGF-I and
downstream Akt/mTOR signalling (Ghosh et al., 2010). For example, in
mouse neural cells, SIRT1 silencing and overexpression increased and
decreased IGF-I and associated Akt signalling, respectively (Sansone
et al., 2013). Similarly, SIRT6 overexpression in mice has been associated
with a reduction in circulating IGF-I (Kanfi et al., 2012a). An exciting
recent link between SIRT1 and IGF-I has been established in a range of
nonskeletal muscle human cell types. When stimulated with exogenous
IGF-I for prolonged periods, cells exhibited reduced SIRT1 deacetylase
activity, increased p53 acetylation and increased senescence, when
compared with cells exposed to acute administration of IGF-I exhibiting
increased proliferation (Tran et al., 2014). Although speculative, reduc-
tions in IGF-I with age could be an attempt to alleviate senescence and
maintain SIRT1 activity (Tran et al., 2014). In SkM, our group has shown
that the induction of apoptosis, by low-dose tumour necrosis factor-
alpha (TNF-a) with the addition of IGF-I, is elevated compared with TNF-a
administration alone. Death was associated with increased SIRT1 mRNA
levels, which when suppressed using SIRT1 siRNA, culminated in
exacerbated, not reduced, apoptosis (Saini et al., 2008, 2012). Overall
suggesting that under conditions of both anabolic and catabolic
conflicts, SIRT1 was important to the maintenance of survival in skeletal
muscle cells. Therefore, SIRT1 appeared fundamental in negatively
regulating IGF-I basally, yet in the presence of inflammatory catabolic
stress (Saini et al., 2008, 2012), or where IGF-I exposure was prolonged
enough to induce cell death (Tran et al., 2014), SIRT1 was important in
maintaining survival. It is also worth noting that SRT2104, a synthetic
small molecular activator of SIRT1, reduced circulating TNF-a in mice
(Mercken et al., 2014). Suggesting a potential regulatory loop between
SIRT1 and TNF-a, yet this link in SkM is yet to be directly established. This
concept is particularly relevant in aging muscle where chronic low-level
TNF-a exposure and changing IGF-I concentrations are strongly associ-
ated with muscle wasting in vivo and the pathologies of sarcopenia and
cachexia (Li & Reid, 2000; Meadows et al., 2000; Foulstone et al., 2001;
Greiwe et al., 2001; Bruunsgaard et al., 2003a,b; Bruunsgaard &
Pedersen, 2003; Stewart et al., 2004; Grohmann et al., 2005; Li et al.,
2005; Saini et al., 2006, 2008, 2010, 2012).
Fig. 1 Depicts the extracellular and
intracellular signaling molecules involved in
the cross-talk between skeletal muscle mass
regulation and life/health-span modulation.
Genetic or pharmacological suppression of
IIS, TOR and Sirtuin pathways increase
organism life/health-spans. However, these
pathways are fundamental in protein
synthesis, growth, differentiation and
survival in skeletal muscle into old age. This
figure therefore provides the potential
molecular and cross-talk modulators for this
paradigm of lifespan versus muscle mass
maintenance with age.
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In addition to its role in regulating IGF-I and survival in the presence of
aberrant IGF-I, SIRT1 may also play a role in negatively regulating mTOR.
SIRT1 (/) mouse embryonic fibroblasts (MEFs) and human HELA cells
depleted of SIRT1 using shRNAi resulted in elevated mTOR signalling,
which was not abolished by leucine deprivation (Ghosh et al., 2010). In
the same study, SIRT1 activators and inhibitors (resveratrol/nicotinamide)
reduced and increased mTOR activity, respectively (Ghosh et al., 2010).
SIRT1 activation following resveratrol administration in myoblasts inhib-
ited IGF-I-associated signalling (Akt) and abolished leucine-stimulated
increases in mTOR (Liu et al., 2010). These studies suggest that any
changes in SIRT1 with age in response to catabolic stress or nutrient
restriction could potentially impact on mTOR function and result in
altered regeneration. Overall, these data present potential negative
regulation by SIRT1 on pathways such as Akt/mTOR linked to SkM
growth. On the contrary, recent work by Hong et al. (2014) suggested
that SIRT1 and SIRT2 deacetylate the substrate of mTOR, S6K, specifically
on mTOR-dependant phosphorylation site Thr-389. In this case, acety-
lation blocked S6K activation and thus, deacetlyation by the sirtuins may
actually be involved in the phosphorylation of S6K (Hong et al., 2014).
Furthermore, in cardiac muscle, SIRT1 can also deacetylate Akt and PDK,
enabling binding to phosphatidylinositol 3,4,5-trisphosphate [PIP(3)], and
thus its localization to the membrane where PDK can subsequently
facilitate Akt phosphorylation (Sundaresan et al., 2011). Sirtuin activa-
tion, however, specifically in SkM tissue or cells through overexpression
in rodent models or supplementation of resveratrol/its analogues in
humans, requires further investigation to decipher its role in negatively
or positively regulating SkM mass. Importantly, based on evidence
described above, the reductions in IGF-I seen with age could be an
attempt to increase SIRT1 to harness its role in cell survival especially
when under a catabolic cytokine stress (e.g. TNF-a) that as mentioned
above, is chronically elevated in the circulation and skeletal muscle with
age (and discussed in more detail directly below).
Sirtuins and their role in survival and differentiation under
catabolic stress in skeletal muscle cells
Despite this apparent trade-off with survival vs. growth, our group has
shown that activation of SIRT1 in murine myoblasts following resveratrol
administration can begin to rescue differentiation of SkM cells following
catabolic stimulation by TNF-a (Saini et al., 2012). This is important
when considering that TNF-a is chronically increased in the aging
circulation and that it is produced by muscle itself (Greiwe et al., 2001;
Bruunsgaard et al., 2003a,b; Bruunsgaard & Pedersen, 2003). In
agreement with our group, resveratrol can reverse the negative impact
of TNF-a on myotube hypertrophy (Wang et al., 2014). Similarly,
activation of SIRT1 using SRT2104 attenuated SkM mass losses of the
gastrocnemius and soleus in mice following 2 weeks of hindlimb
unloading (Mercken et al., 2014). SRT2104 also extended lifespan,
without reducing SkM weight into old age (Mercken et al., 2014).
Therefore, as well as an important role in myoblast survival, SIRT1 may
also be involved in maintaining adequate differentiation, hypertrophy
and attenuating atrophy in vivo during stress stimuli such as those
experienced with chronic inflammation or disuse.
Finally, it is important to consider that changes in the [NAD+]/[NADH]
ratio occur during skeletal muscle differentiation and this changing ration
in turn can regulate SIRT1 (Sartorelli & Caretti, 2005). A reduction in the
[NAD+]/[NADH] ratio coincides with skeletal myogenesis, whereas an
increase is associated with impaired myogenesis (Fulco et al., 2003). It is
clear, however, that differences prevail in terms of derived data. Indeed,
Fulco et al. (2008) suggested that increasing SIRT1 activity in mouse and
human SkM cells impaired differentiation and myosin heavy chain
production (Fulco et al., 2003, 2008), which differs from our work with
TNF-a, but complements more recent unpublished work where under
control conditions, resveratrol increased proliferation in both control and
artificially agedmyoblasts but impaired differentiation (Deane CS, Hughes
DC, Sharples AP, unpublished). An increase in proliferation, inhibition of
p21cip and p27kip and a reduction in differentiation following SIRT1
overexpression in rat myoblasts have also been previously reported
(Rathbone et al., 2009). Therefore, despite its proposed negative regu-
lation of IGF-I/Akt/mTOR, SIRT1 seems to be fundamental to SkM cell
survival, enabling proliferation and impairing differentiation under control
conditions, yet protecting differentiation under conditions of stress.
Importantly, the impact of activating SIRT in aged SkM cells/tissue basally
or under stress remains to be fully determined especially, we hypothesise,
in situations of dietary restriction that directly regulate the NAD/NADH
ratio and impact on SIRT expression.
Sirtuins: regulators of longevity and survival vs. activators of
protein degradation in SkM via FOXO transcription factors
In addition to its role in SkMproliferation, SIRT1 has also been implicated in
controlling protein degradative pathways, specifically via forkhead box
protein O (FoxO) transcription factors. These transcription factors are
involved in targeting and activatingmembers of the ubiquitin proteasome,
such as muscle atrophy F-box (MAFbx/atrogin1), muscle RING finger 2
(MuRF1), and autophagy–lysosome pathways involved in protein degra-
dation (Sandri et al., 2004; Edstrom et al., 2006; Sandri, 2008). SIRTs have
been shown to activate both FOXO3a gene expression and deacetylate
FOXO3a, thereby activating FOXO DNA binding and elevating the
expression of target genes such as p27(Kip1), manganese superoxide
dismutase and Bim, proteins associated with cell cycle arrest, oxidative
stress and apoptosis respectively (Brunet et al., 2004; Wang et al., 2007;
Jacobs et al., 2008). The activation of FOXO transcription factors by the
SIRT family appears to, however, impair the ability of FOXO to promote cell
apoptosis, instead shifting its function towards oxidative stress resistance
and DNA repair (Brunet et al., 2004; Greer & Brunet, 2005; Wang et al.,
2007). It is also well established that overexpression of FOXO can extend
lifespan in drosophila (Giannakou et al., 2004;Min et al., 2008; Alic et al.,
2014). Interestingly, in TNF-a-stimulated SkM cells the activation of SIRT1
via resveratrol restored Akt/mTOR/S6K and 4E-BP1 signalling and reduced
FOXO1but not FOXO3aprotein levels, all ofwhichwereunchangedbasally
(Wang et al., 2014). Therefore, the role for SIRT1 activation on FOXO3a in
SkM tissue with age requires further investigation. FOXO1 and its role in
oxidative stress resistance in aging SkM also requires attention, especially
following catabolic stress or dietary restriction where SIRT1 elevation is
associated with survival. It is worth mentioning here that class I histone
deactylases (HDACs) (sirtuinsare class III HDACS)havealso been linkedwith
activating FOXO3a and the SkM-atrophy programme (via MAFbx/atrogin-
1) during nutrient deprivation and disuse-induced atrophy (Beharry et al.,
2014). Potentially this suggests that FOXO1 and FOXO3a aremodulated by
class I andclass IIIHDACs, respectively, andthismayaccount for someof the
discrepancy detailed above. The role of the SIRTs in SkM is intriguing and
warrants further investigation, specifically the promotion of longevity via
resistance to oxidative stress vs. increased protein degradation with aging.
Sirtuins and NF-Kb and their roles in longevity and skeletal
muscle loss with age
While discussing protein degradation above, it is worth noting that SIRT6
has been associated with modulating lifespan via nuclear factor jB
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(NF-Kb) signalling (Yeung et al., 2004; Kanfi et al., 2012b). The inhibition
of NF-Kb delays DNA damage, cellular senescence and oxidative stress
during aging (Tilstra et al., 2012). However, in SkM, NF-Kb is another
important protein where cytokine and oxidative stress signalling
converge to reduce myoblast differentiation, induce atrophy and
increase protein degradation (Langen et al., 2001; Hunter & Kandarian,
2004; Lu et al., 2012). SIRT6 attenuates NF-Kb signalling through histone
deacetylation of NF-Kb gene promoter regions and suppresses those
genes associated with senescence and aging (Kawahara et al., 2009).
The deletion of SIRT6 in KO mice also results in shortened lifespan and
significantly reduced body weight, suggesting an important develop-
mental and postnatal role for this protein:protein interaction (Mosto-
slavsky et al., 2006). Studies by our laboratory suggest that inhibition of
NF-Kb can promote delayed myoblast apoptosis in the presence of TNF-a
(Stewart et al., 2004). It is, however, worth noting that there was no
change in NF-Kb during disuse atrophy (2 weeks hindlimb suspension)
even in the presence of SRT2104 (Mercken et al., 2014). Interestingly,
very recent work suggests SIRT activation in murine models via SRT2104
causes a reduction in the ratio of phosphorylated NF-Kb to total protein
(Mercken et al., 2014). This therefore suggests that SIRT1 and SIRT6 may
be important in reducing NF-Kb. Overall, SIRT1 and/or SIRT6 may
regulate lifespan as a consequence of reduced IGF-I signalling and
potentially attenuate the effects of inflammatory NF-Kb signalling.
Effect of Dietary Restriction (DR) on longevity and
skeletal muscle mass
Calorie restriction is defined as a reduction in energy intake, while
maintaining nutrient intake, relative to that consumed normally by
individuals with free (ad libitum) access to food (Selman, 2014). For the
purposes of this review, dietary restriction (DR) will incorporate both
calorie restriction and those interventions in which macro/micronutrients
are altered without any overall change in energy intake. DR is the most
reproducible intervention, to date, to extend medium and maximum
lifespan in various model species (Mair & Dillin, 2008; Speakman &
Selman, 2011; Selman, 2014). In mice, there seems to be a strain-
specific association with DR and longevity, and in primates, the link
between lifespan extension and DR may also be confounded by genetic
heterogeneity (reviewed by Selman, 2014). Nevertheless, DR reduces
incidence and severity of various pathological conditions in rodents and
primates, which are leaner, and display reductions in insulin resistance,
glucose intolerance, cognitive decline and immune dysfunction (Masoro
et al., 1982; Barger et al., 2003; Selman et al., 2005; Mattison et al.,
2012), indicating DR per se is beneficial for health.
Trade-off between cellular energy metabolism and growth in
skeletal muscle with dietary restriction
The intuitive impact of chronic DR on SkM mass is that over time,
absolute muscle mass decreases. This is not surprising if you consider
that in the presence of nutrient restriction, the cell shifts away from
growth in an attempt to survive. Further, protein from SkM can provide
energy during severe nutrient restriction. One of the first studies to
demonstrate this and to establish the molecular link between AMPK
energy sensing and cellular growth through mTOR/S6K signalling was
that of Inoki and collegues (Inoki et al., 2003). Using various cell types
(HEK293, MEF, EEF, LEFs) under starvation conditions, they reported
increased AMPK activity and phosphorylated tuberous sclerosis 2 (TSC2).
The TSC2 inhibited mTOR and other substrates, including S6K, 4EBP-1
and EIF2, which resulted in reduced cell size and growth rates. The role
of TSC2 in this process was confirmed in TSC2 KO cells, which grew and
maintained normal size in the presence of starvation. The AMPK
activation of TSC2 and inhibition of mTOR therefore appears central in
responses to energy deprivation. Fascinating but perhaps unintuitively,
given the data thus far, DR appears to delays or prevent age-related loss
of SkM mass in rats and rhesus monkeys via attenuation of DNA
damage, proteosomal machinery, autophagy, inflammatory signalling
and mitochondrial abnormalities (Aspnes et al., 1997; Phillips & Leeu-
wenburgh, 2005; Hepple et al., 2008; McKiernan et al., 2011). Indeed,
short-term DR can potentially increase SkM stem cell availability and
subsequent SkM repair following cryo-injury in young and old mice
(Cerletti et al., 2012). In a recent in vivo study, chronic DR (by 30% of
recommended daily intake) for a period ranging from 4 to 20 years
(mean 9.6 years), resulted in reduced IGF-I levels, and a threefold
reduction in Akt mRNA/ 30–50% reduction in Akt activity, together with
increased FOXO3a and FOXO4 expression (Mercken et al., 2013). These
changes in FOXO were reported to modify several genes linked to
longevity including genes associated with stress resistance, antioxidants,
DNA repair, protein turnover and cell death (Mercken et al., 2013). In
SkM however, this shift away from growth towards stress resistance,
would potentially reduce protein synthesis and increase degradation over
time (Sandri et al., 2004; Edstrom et al., 2006). Furthermore, superoxide
dismutase 2 (SOD2) expression, a transcriptional target of FOXOs, was
increased under DR, as was DNA damage-binding protein 1 (DDB1),
both key regulators of DNA repair. Further, cyclin D2 was significantly
downregulated during moderate DR, as a fundamental orchestrator of
cell cycle progression for proliferation or growth (Mercken et al., 2013).
Interestingly, DR in rats also reduced levels of the inflammatory cytokine
TNF-a and associated signalling (Phillips & Leeuwenburgh, 2005). These
studies therefore suggest that chronic moderate (~30%) DR results in
transcriptional reprogramming, which shift cellular regulation from
growth to maintenance/repair and lifespan activities, while potentially
reducing local inflammation. Perhaps most importantly, humans and
mice on DR diets had higher lean SkM mass-to-fat mass ratios (Mercken
et al., 2013). Therefore, there is potentially an optimal level of DR which
has the beneficial effect of longevity, while perhaps preventing growth
but not inducing muscle loss. Although overall SkM mass is likely to be
reduced by long-term DR, the ratio of lean mass to fat mass may be
greater and total body weight maybe reduced, a signature conducive of
reduced metabolic disease risk. It remains to be determined, however,
whether chronic DR changes SkM strength or the proportions of
extracellular matrix to muscle tissue, or alters contractile properties and
force per cross-sectional area/muscle quality. Indeed, the influence on
force production following DR could be affected by fibre type, as type I
fibres were ~62% larger after DR (30% DR for 12 years) in rhesus
monkeys vs. control. Furthermore, in this study it was observed that
there was delay in type II fibre atrophy with age (McKiernan et al.,
2011). So while data of long-term studies are limited, they do suggest
potential for both longevity and muscle health.
Despite this body of work, several other studies oppose these
findings. For example, although different to sustained DR, Lee and
Goldberg investigated the impact of acute fasting in mice and showed
that this resulted in a reduction in SIRT1 activity and an increase in the
atrogenes MuRF-1 and atrogin-1, which ultimately led to a significant
decrease in SkM mass (Lee & Goldberg, 2013). Dietary restriction
(30%) for 6 weeks, in combination with exercise, also reduced
gastrocnemius SkM weight and cross-sectional area in comparison with
similarly exercised mice under ad libitum feeding (Park et al., 2013).
However, it should be noted that this study did not include a DR or
ad libitum alone group. This does, however, highlight the temporal role
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of short-duration fasting vs. longer duration DR and the modulation of
SIRT1 (McKiernan et al., 2012; Mercken et al., 2013). DR in combination
with physical activity and its impact on SkM phenotypes therefore
requires further investigation. Finally, it is unlikely that DR is a pragmatic
intervention for humans, given that there is a considerable level of
motivation and restraint required, where DR mimetics maybe more
practical as reviewed previously by Selman et al. (Selman, 2014).
Roles of amino acid feeding or high-protein diets in
association with calorie restriction: potential impact
on skeletal muscle mass vs. disease and longevity
One of the issues with DR is the contribution of total calories from
carbohydrates vs. proteins. Most studies do not differentiate between
the two. It is well established that protein intake can enhance muscle
protein synthesis in a dose-responsive manner in young and old adults
(Cuthbertson et al., 2005; Moore et al., 2009). Furthermore, increasing
dietary protein can help maintain SkM mass during periods of disuse
(reviewed in Wall & van Loon, 2013) and induce greater increases in
skeletal muscle hypertrophy following chronic supplementation when
combined with exercise (resistance) vs. exercise alone (meta-analysis
Cermak et al., 2012). Indeed, there is substantial support to suggest
that with DR, overall weight loss is no different with higher protein
intakes vs. DR alone (Sacks et al., 2009; de Souza et al., 2012). With
some acute trials showing that fat mass decreases while SkM is spared
(Krieger et al., 2006), importantly, exercise in combination with higher
protein content in DR diets seems to have a SkM maintaining effect
(Garthe et al., 2011; Josse et al., 2011; Mojtahedi et al., 2011), without
negative impact on markers of mitochondrial biogenesis, albeit after
acute fasting in humans (Taylor et al., 2013). Interestingly, undertaking
DR that is protein rich reduces both body mass and percentage body fat,
with associated reductions in circulating insulin and IGF-I levels (Maestu
et al., 2010), alluding to potential benefits for lifespan while potentially
maintaining SkM mass. Supplementation with branched-chain amino
acids (BCAAs) such as leucine, isoluecine, valine or metabolites of
leucine such as b-hydroxy-b-methylbutyrate (HMB) have become a
favoured intervention as they have been shown to activate mTOR and
protein synthesis in SkM to a greater extent compared with other
essential/nonessential amino acids (Atherton et al., 2010; Pimentel et al.,
2011; Churchward-Venne et al., 2012; Salles et al., 2013). Leucine alone
can activate protein synthesis in humans to the same extent as whey
protein and mixed essential amino acids plus leucine when administered
1–3 h postresistance exercise (Churchward-Venne et al., 2012). How-
ever, the requirement for whey protein for optimal protein synthesis 3–
5 h postexercise is acknowledged (Churchward-Venne et al., 2012;
Phillips, 2014). Previously, Mourier and colleagues observed that DR in
human males (wrestlers) when combined with supplementation of mixed
BCAAs led to a reduction in total body mass and fat mass (17.3%),
although SkM mass was unchanged (Mourier et al., 1997). This suggests
a potential role for BCAAs in maintaining SkM mass under DR
conditions. Furthermore, a recent study highlighted that HMB attenuated
the loss of SkM mass observed following DR in murine exercise models
(Park et al., 2013). Mice underwent exercise at 6 m.min1 run for 1 h,
three times a week alone or combined with HMB and/or DR. The HMB
animals had higher lean mass than the training alone group. Grip
strength decreased under DR, but was maintained in DR mice supple-
mented with HMB. Interestingly, gastrocnemius mass and myofibre
cross-sectional area were greater with HMB in the presence of a DR diet
compared to DR alone, albeit there were no data reported for either ad
libitum or HMB alone supplemented mice (Park et al., 2013). This latter
finding was also associated with the reduced ubquitin ligase, MAFbx,
alluding to reduced protein degradation. Surprisingly however, Akt and
mTOR mRNA were elevated under DR conditions in SkM. Speculation
based on evidence presented in above sections suggests this may be due
to increased SIRT1, yet this hypothesis requires further investigation.
Therefore, in the light of the above discussion it would be prudent to
investigate, on a background of DR, how AMPK and SIRT1 (energy
sensing) change in the presence of BCAAs and the way in which they
impact on Akt/mTOR (growth) via the molecular modulators of TSC1/
TSC2 (discussed above and seen in Fig. 1).
Finally, it is important to note that increased protein intake, especially
BCAAs, stimulates targets such as mTOR and S6K, which are
downstream of IIS, the precise signalling which is reportedly suppressed
to enable longevity and to reduce age-related disease. This therefore
contributes to the recently debated paradigm whereby downstream IIS
signalling is still activated, yet independently of IGF binding to its
receptor, and thus protein synthesis in SkM mass may be maintained
with increased protein intake during aging. However, it has been
conversely suggested that increased protein intake may increase
incidence of diseases, such as cancer, and thus impact negatively on
longevity (Renehan et al., 2004). Indeed, it is known that cancer
patients who do not respond to chemotherapy or are end-stage patients
have reduced protein diets that, while potentially adding to the
chronically inflamed milieu that causes SkM loss (cachexia), can slow
tumour progression. Examples include animal models where DR can
attenuate tumorigenesis via inhibition of mTOR, whereas leucine
feeding can increase pancreatic tumour growth in both lean and
overweight mice (Vellai et al., 2003; Bjornsti & Houghton, 2004;
Hursting et al., 2010; Lashinger et al., 2011; Liu et al., 2014). Restrict-
ing the amino acid methionine can also limit tumour growth, and both
methionine and essential amino acid restriction increase lifespan in
rodents (Richie et al., 1994; Miller et al., 2005; Emran et al., 2014;
Sinha et al., 2014). Overall, these studies suggest caution for cancer
patients and amino acid supplementation, even those who suffer with
muscle loss (Liu et al., 2014). The role of higher protein diets with age
and the impact on disease risk and early mortality have recently received
a high level of attention. Cohorts of 6381 adults aged 50 and over were
studied for their habitual dietary intake and macronutrient composition
with corresponding disease and mortality incidence (Levine et al., 2014).
Between the ages of 60 and 65, those who reported high animal-
derived protein intake had a 75% increased risk in overall mortality and
a fourfold increase in cancer risk during the subsequent 18 years. If
aged over 65 years of age, however, higher protein intake was
associated with reduced cancer risk, but a fivefold increased risk of
diabetes. These results therefore suggested that a low-protein diet is
potentially beneficial in midlife; however, the benefits reduce with age.
In an attempt to compliment these studies with mechanisms, high-
protein diets were implemented in middle-aged mice, where the
increase in GH/IGF signalling observed was associated with increased
progression of tumours. The authors did, however, suggest that low
protein impacted negatively on SkM mass in aged mice (Levine et al.,
2014). In agreement with this study, an investigation published in the
same issue as that by Levine et al. using a Geometric Framework
approach to investigate the contributions of protein-to-carbohydrate
ratios and their association with increased longevity in mice, suggested
that healthy aging is not as a consequence of high-protein low calorie
diets, but low-protein (especially BCAAs) diets, with the remaining
macronutrients being made up of carbohydrate rather than fat (Solon-
Biet et al., 2014). Also, data by Levine et al. have been scrutinized in
terms of the methodological design. For example, 24-h dietary recalls
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suggesting up to 18 years of habitual diet are potentially not appro-
priate to account for lifelong habitual dietary intake. Furthermore, the
grouping of the low- to high-protein categories [based on Institute of
Medicines’ (IOM) Acceptable Macronutrient Distribution Range] has also
received attention, where the low-protein group would probably be
classed as protein deficient. It is also worth stating that in the total
cohort (50 years and over), the level of protein intake was not
associated with differences in all-cause, cancer or CVD mortality.
Importantly, however the study did find a significant association
between the subjects aged 50–55, higher protein consumption and
cancer/mortality. Amongst 2253 subjects, the risk of cancer and
mortality was increased in the high-protein subjects who also had
higher IGF-I serum levels. It is indeed, established that people in the
highest circulating IGF-I quintiles are at the highest risk of developing
cancer (Hankinson et al., 1998; Kaaks et al., 2000; Giovannucci et al.,
2003) and the role of IGF-I and associated signalling in cancer cells and
tumour development is fairly robust (Pollak et al., 2004; Guevara-
Aguirre et al., 2011). It is important to note that these are similar
pathways to growth/amino acid stimuli required for SkM maintenance
with age. The future paradigm we should be addressing would
therefore be the trade-off between maintenance of SkM mass vs.
longevity, potentially at the expense of age-related diseases.
Conclusion
The understanding of aging and the development of interventions to
increase healthy lifespan have been greatly aided by the development of
genetic mutants for IIS, TOR and sirtuin pathways as well as the use of
pharmacological agents known to act on these pathways. However, all
of these pathways are fundamental in regulating the trade-off between
survival and maintenance vs. growth, particularly in skeletal muscle
where age-associated losses in SkM mass and function are observed
with advancing age. This provides a paradigm in which there is
potentially reduced regenerative capacity within SkM tissue with age in
an attempt to promote longevity of the organism and survival within the
tissue. Optimizing dietary restriction (DR) or using DR mimetics in
combination with amino acid administration may be critical interven-
tions to help attenuate SkM loss with advancing age, while enabling
healthy aging.
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